1. Osadchii OE. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc Drugs Ther 2007; in press.
2. Endoh M, Hori M. Acute heart failure: inotropic agents and their clinical uses. Expert Opin Pharmacother 2006;7:2179–202.
3. Blinks JR, Endoh M. Modification of myofibrillar responsiveness to Ca++ as an inotropic mechanism. Circulation 1986;73:III-85–98.
4. Katano Y, Endoh M. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine. J Cardiovasc Pharmacol 1992;20:715–22.
5. Endoh M, Katano Y, Kawabata Y. Subcellular mechanism of action of a novel cardiotonic quinolinone derivative POC-18790 in mammalian cardiac muscle: selective inhibition of isozymes of phosphodiesterase and contractile regulation. In: Dhalla NS, Beamish RE, Takeda N, Nagano M, editors. The failing heart. Philadelphia: Lippincott-Raven, 1995. p. 361–75.